دورية أكاديمية
S-Ketamine in the treatment of depressive emergencies: a cases series of patients in a suicidal crisis
| العنوان: | S-Ketamine in the treatment of depressive emergencies: a cases series of patients in a suicidal crisis |
|---|---|
| المؤلفون: | B. Baune, Z. Susam, V. Falcone, C. Knümann, P. Sarkheil, E. Kavakbasi |
| المصدر: | European Psychiatry, Vol 65, Pp S565-S565 (2022) |
| بيانات النشر: | Cambridge University Press, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Psychiatry |
| مصطلحات موضوعية: | s-ketamine, depression, suicidal ideation, emergency psychiatry, Psychiatry, RC435-571 |
| الوصف: | Introduction Psychiatric emergencies in Major Depressive Disorder (MDD) are characterised by multiple types of symptoms including risk of self-harm and suicidal ideation. S-ketamine intranasally (Spravato) has recently been shown to help alleviate symptoms during depressive emergencies. In this case-series, we detail the clinical effects and usability of S-ketamine applied intranasally in a psychiatric emergency setting. Objectives To describe the effects of S-Ketamine on depressive crises associated with suicidality and self-harm in a psychiatric emergency setting. Methods Patients with MDD in a psychiatric emergency were provided with intranasal S-Ketamine according to clinical indication in routine clinical care in a University inpatient setting. Clinical characteristics were assessed in a standardised manner and symptom measures were applied pre-and posttreatment. Experience with 10 patients is systematically described in this case-series. Results Patients had a primary diagnosis of MDD accompanied by a variety of secondary psychiatric comorbidity. Among these 10 patients, the majority were female (70 %) and the mean age was 49.5 yrs (range 26-66). All cases were considered treatment resistant and suffered severe acute suicidal ideation. Across all cases, pre-treatment MADRS was 37 on average (range 20-47) indicating a severe form of MDD. High severity was confirmed in elevated BDI scores (pre-treatment 39). Post-treatment, MADRS scores were reduced to 18 on average, alongside BDI scores (mean 24). S-ketamine administration was well-tolerated and side effects such as dissociation were of short-lived duration. Conclusions S-Ketamine intranasally can be safely and effectively administered in an acute psychiatric setting to treat psychiatric emergencies. Disclosure BTB received honoraria for consultancy and presentations from AstraZeneca, Bristol-Myers Squibb, Lundbeck, Pfizer, Servier, Wyeth, LivaNova, Janssen, Novartis, Otsuka, Angelini. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 0924-9338 1778-3585 |
| Relation: | https://www.cambridge.org/core/product/identifier/S0924933822014468/type/journal_article; https://doaj.org/toc/0924-9338; https://doaj.org/toc/1778-3585 |
| DOI: | 10.1192/j.eurpsy.2022.1446 |
| URL الوصول: | https://doaj.org/article/438d258fc3f74178b2c48437ae8b4c5a |
| رقم الأكسشن: | edsdoj.438d258fc3f74178b2c48437ae8b4c5a |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 09249338 17783585 |
|---|---|
| DOI: | 10.1192/j.eurpsy.2022.1446 |